Although decreased Dab2 mRNA levels were observed in all human breast cancer samples analyzed, irrespective of tumour grade, the decreased expression of Dab2 in the DCIS sample suggests that Dab2 loss occurs early in breast cancer progression (Figure 1 and Supplementary Table 1). The gene discussed is DAB2; the disease is breast cancer.